Revisiting Regulations and Policies
US Federal Regulation of AI Is Likely To Be Lighter, but States May Fill the Void
The Trump administration may bring a light regulatory approach to AI, and a lack of consensus within both major parties means federal AI legislation is unlikely, with states potentially filling this regulatory and legislative void.
Trump 2.0 Could Mean a More Bank- and Fintech-Friendly Environment
Incoming banking regulators are likely to make industry-friendly changes in areas such as supervision, capital and liquidity, and digital assets. Banks and fintechs may want to position themselves for M&A and bank chartering opportunities.
Some States Prepare for the Expected Rollback of Biden Environmental Regulations
While the new administration is expected to roll back many of President Biden’s climate and other environmental regulations, many blue states are gearing up to fill what is perceived as an upcoming gap in federal environmental regulation.
Employers’ DEI Initiatives Are Likely To Be Targeted in the Second Trump Administration
The new administration is likely to oppose corporate DEI programs, and conservative activists will continue to pressure companies, but carefully crafted policies on workforce diversity may still be able to withstand legal challenges.
Approach to Corporate Enforcement May Become More Business-Friendly
The incoming administration is expected to take a more lenient approach to prosecuting entities and pull back from the pursuit of novel, aggressive theories. A friendlier approach to cryptocurrency is also likely.
Possible Tax Reforms Could Run Up Against Deficit and Debt Concerns
Key tax issues facing the new administration include extending international tax provisions and tax benefits for domestic businesses, responding to the global minimum tax initiative and offsetting revenue losses from tax cuts.
Drug Pricing and Health Care Fraud Remain Key Issues
Drug pricing is expected to be a priority for the new administration, and health care fraud and data privacy are likely to remain enforcement focuses. OMUFA reauthorization could lead to legislation around other hot-button FDA issues.